PittsburghV1, PubMed, Checkpoint, bibRecord, 000302

Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.

Identifieur interne : 000302 ( PubMed/Checkpoint ); précédent : 000301; suivant : 000303

Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.

Auteurs : Zachary A. Marcum [États-Unis] ; Julia Driessen [États-Unis] ; Carolyn T. Thorpe [États-Unis] ; Julie M. Donohue [États-Unis] ; Walid F. Gellad [États-Unis]

Source :

The Annals of pharmacotherapy [ 1542-6270 ] ; 2015.

RBID : pubmed:25515869

Descripteurs français

KwdFr :
- Diabète (traitement médicamenteux), Diabète (économie), Diabète (épidémiologie), Femelle, Humains, Hypoglycémiants (usage thérapeutique), Hypoglycémiants (économie), Incrétines (usage thérapeutique), Incrétines (économie), Medicare part D (USA) (économie), Metformine (usage thérapeutique), Metformine (économie), Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Sulfonylurées (usage thérapeutique), Sulfonylurées (économie), Thiazolidinediones (usage thérapeutique), Thiazolidinediones (économie), États-Unis d'Amérique (épidémiologie), Études transversales.
MESH :
- traitement médicamenteux : Diabète.
- usage thérapeutique : Hypoglycémiants, Incrétines, Metformine, Sulfonylurées, Thiazolidinediones.
- économie : Diabète, Hypoglycémiants, Incrétines, Medicare part D (USA), Metformine, Sulfonylurées, Thiazolidinediones.
- épidémiologie : Diabète, États-Unis d'Amérique.
- Femelle, Humains, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Études transversales.
Wicri :
- geographic : États-Unis.

English descriptors

KwdEn :
- Aged, Aged, 80 and over, Cross-Sectional Studies, Diabetes Mellitus (drug therapy), Diabetes Mellitus (economics), Diabetes Mellitus (epidemiology), Female, Humans, Hypoglycemic Agents (economics), Hypoglycemic Agents (therapeutic use), Incretins (economics), Incretins (therapeutic use), Male, Medicare Part D (economics), Metformin (economics), Metformin (therapeutic use), Sulfonylurea Compounds (economics), Sulfonylurea Compounds (therapeutic use), Thiazolidinediones (economics), Thiazolidinediones (therapeutic use), United States (epidemiology).
MESH :
- chemical , economics : Hypoglycemic Agents, Incretins, Metformin, Sulfonylurea Compounds, Thiazolidinediones.
- geographic , epidemiology : United States.
- drug therapy : Diabetes Mellitus.
- economics : Diabetes Mellitus, Medicare Part D.
- epidemiology : Diabetes Mellitus.
- chemical , therapeutic use : Hypoglycemic Agents, Incretins, Metformin, Sulfonylurea Compounds, Thiazolidinediones.
- Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Humans, Male.

Abstract

When incretin mimetic (IM) medications were introduced in 2005, their effectiveness compared with other less-expensive second-line diabetes therapies was unknown, especially for older adults. Physicians likely had some uncertainty about the role of IMs in the diabetes treatment armamentarium. Regional variation in uptake of IMs may be a marker of such uncertainty.

DOI: 10.1177/1060028014563951
PubMed: 25515869

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 000508
to stream PubMed, to step Curation: 000508

Links to Exploration step

pubmed:25515869

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.</title>
<author><name sortKey="Marcum, Zachary A" sort="Marcum, Zachary A" uniqKey="Marcum Z" first="Zachary A" last="Marcum">Zachary A. Marcum</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA zam12@pitt.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Driessen, Julia" sort="Driessen, Julia" uniqKey="Driessen J" first="Julia" last="Driessen">Julia Driessen</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Thorpe, Carolyn T" sort="Thorpe, Carolyn T" uniqKey="Thorpe C" first="Carolyn T" last="Thorpe">Carolyn T. Thorpe</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Donohue, Julie M" sort="Donohue, Julie M" uniqKey="Donohue J" first="Julie M" last="Donohue">Julie M. Donohue</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Gellad, Walid F" sort="Gellad, Walid F" uniqKey="Gellad W" first="Walid F" last="Gellad">Walid F. Gellad</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2015">2015</date>
<idno type="RBID">pubmed:25515869</idno>
<idno type="pmid">25515869</idno>
<idno type="doi">10.1177/1060028014563951</idno>
<idno type="wicri:Area/PubMed/Corpus">000508</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000508</idno>
<idno type="wicri:Area/PubMed/Curation">000508</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000508</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000508</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000508</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.</title>
<author><name sortKey="Marcum, Zachary A" sort="Marcum, Zachary A" uniqKey="Marcum Z" first="Zachary A" last="Marcum">Zachary A. Marcum</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA zam12@pitt.edu.</nlm:affiliation>
<country wicri:rule="url">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Driessen, Julia" sort="Driessen, Julia" uniqKey="Driessen J" first="Julia" last="Driessen">Julia Driessen</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Thorpe, Carolyn T" sort="Thorpe, Carolyn T" uniqKey="Thorpe C" first="Carolyn T" last="Thorpe">Carolyn T. Thorpe</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Donohue, Julie M" sort="Donohue, Julie M" uniqKey="Donohue J" first="Julie M" last="Donohue">Julie M. Donohue</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
<author><name sortKey="Gellad, Walid F" sort="Gellad, Walid F" uniqKey="Gellad W" first="Walid F" last="Gellad">Walid F. Gellad</name>
<affiliation wicri:level="4"><nlm:affiliation>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA</wicri:regionArea>
<placeName><region type="state">Pennsylvanie</region>
<settlement type="city">Pittsburgh</settlement>
</placeName>
<orgName type="university">Université de Pittsburgh</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j">The Annals of pharmacotherapy</title>
<idno type="eISSN">1542-6270</idno>
<imprint><date when="2015" type="published">2015</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Sectional Studies</term>
<term>Diabetes Mellitus (drug therapy)</term>
<term>Diabetes Mellitus (economics)</term>
<term>Diabetes Mellitus (epidemiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypoglycemic Agents (economics)</term>
<term>Hypoglycemic Agents (therapeutic use)</term>
<term>Incretins (economics)</term>
<term>Incretins (therapeutic use)</term>
<term>Male</term>
<term>Medicare Part D (economics)</term>
<term>Metformin (economics)</term>
<term>Metformin (therapeutic use)</term>
<term>Sulfonylurea Compounds (economics)</term>
<term>Sulfonylurea Compounds (therapeutic use)</term>
<term>Thiazolidinediones (economics)</term>
<term>Thiazolidinediones (therapeutic use)</term>
<term>United States (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Diabète (traitement médicamenteux)</term>
<term>Diabète (économie)</term>
<term>Diabète (épidémiologie)</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hypoglycémiants (usage thérapeutique)</term>
<term>Hypoglycémiants (économie)</term>
<term>Incrétines (usage thérapeutique)</term>
<term>Incrétines (économie)</term>
<term>Medicare part D (USA) (économie)</term>
<term>Metformine (usage thérapeutique)</term>
<term>Metformine (économie)</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Sulfonylurées (usage thérapeutique)</term>
<term>Sulfonylurées (économie)</term>
<term>Thiazolidinediones (usage thérapeutique)</term>
<term>Thiazolidinediones (économie)</term>
<term>États-Unis d'Amérique (épidémiologie)</term>
<term>Études transversales</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="economics" xml:lang="en"><term>Hypoglycemic Agents</term>
<term>Incretins</term>
<term>Metformin</term>
<term>Sulfonylurea Compounds</term>
<term>Thiazolidinediones</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Diabetes Mellitus</term>
</keywords>
<keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Diabetes Mellitus</term>
<term>Medicare Part D</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Diabetes Mellitus</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Hypoglycemic Agents</term>
<term>Incretins</term>
<term>Metformin</term>
<term>Sulfonylurea Compounds</term>
<term>Thiazolidinediones</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Diabète</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Hypoglycémiants</term>
<term>Incrétines</term>
<term>Metformine</term>
<term>Sulfonylurées</term>
<term>Thiazolidinediones</term>
</keywords>
<keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Diabète</term>
<term>Hypoglycémiants</term>
<term>Incrétines</term>
<term>Medicare part D (USA)</term>
<term>Metformine</term>
<term>Sulfonylurées</term>
<term>Thiazolidinediones</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Diabète</term>
<term>États-Unis d'Amérique</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cross-Sectional Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Femelle</term>
<term>Humains</term>
<term>Mâle</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Études transversales</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">When incretin mimetic (IM) medications were introduced in 2005, their effectiveness compared with other less-expensive second-line diabetes therapies was unknown, especially for older adults. Physicians likely had some uncertainty about the role of IMs in the diabetes treatment armamentarium. Regional variation in uptake of IMs may be a marker of such uncertainty.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25515869</PMID>
<DateCreated><Year>2015</Year>
<Month>02</Month>
<Day>18</Day>
</DateCreated>
<DateCompleted><Year>2015</Year>
<Month>08</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1542-6270</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>49</Volume>
<Issue>3</Issue>
<PubDate><Year>2015</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>The Annals of pharmacotherapy</Title>
<ISOAbbreviation>Ann Pharmacother</ISOAbbreviation>
</Journal>
<ArticleTitle>Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.</ArticleTitle>
<Pagination><MedlinePgn>285-92</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1177/1060028014563951</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">When incretin mimetic (IM) medications were introduced in 2005, their effectiveness compared with other less-expensive second-line diabetes therapies was unknown, especially for older adults. Physicians likely had some uncertainty about the role of IMs in the diabetes treatment armamentarium. Regional variation in uptake of IMs may be a marker of such uncertainty.</AbstractText>
<AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the extent of regional variation in the use of IMs among beneficiaries and estimate the cost implications for Medicare.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">This was a cross-sectional analysis of 2009-2010 claims data from a nationally representative sample of 238 499 Medicare Part D beneficiaries aged ≥65 years, who were continuously enrolled in fee-for-service Medicare and Part D and filled ≥1 antidiabetic prescription. Beneficiaries were assigned to 1 of 306 hospital-referral regions (HRRs) using ZIP codes. The main outcome was adjusted proportion of antidiabetic users in an HRR receiving an IM.</AbstractText>
<AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 29 933 beneficiaries (12.6%) filled an IM prescription, including 26 939 (11.3%) for sitagliptin or saxagliptin and 3718 (1.6%) for exenatide or liraglutide. The adjusted proportion of beneficiaries using IMs varied more than 3-fold across HRRs, from 5th and 95th percentiles of 5.2% to 17.0%. Compared with non-IM users, IM users faced a 155% higher annual Part D plan ($1067 vs $418) and 144% higher patient ($369 vs $151) costs for antidiabetic prescriptions.</AbstractText>
<AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Among older Part D beneficiaries using antidiabetic drugs, substantial regional variation exists in the use of IMs, not accounted for by sociodemographics and health status. IM use was associated with substantially greater costs for Part D plans and beneficiaries.</AbstractText>
<CopyrightInformation>© The Author(s) 2014.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marcum</LastName>
<ForeName>Zachary A</ForeName>
<Initials>ZA</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA zam12@pitt.edu.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Driessen</LastName>
<ForeName>Julia</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thorpe</LastName>
<ForeName>Carolyn T</ForeName>
<Initials>CT</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Donohue</LastName>
<ForeName>Julie M</ForeName>
<Initials>JM</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Gellad</LastName>
<ForeName>Walid F</ForeName>
<Initials>WF</Initials>
<AffiliationInfo><Affiliation>University of Pittsburgh, Pittsburgh, PA, USA VA Pittsburgh Healthcare System, Pittsburgh, PA, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>K07 AG033174</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30 AG024827</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 AG027017</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 HL119246</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>UL1 RR024153</GrantID>
<Acronym>RR</Acronym>
<Agency>NCRR NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01 HS018721</GrantID>
<Acronym>HS</Acronym>
<Agency>AHRQ HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>P30AG024827</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>CDA 09-207</GrantID>
<Acronym>HX</Acronym>
<Agency>HSRD VA</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01HL119246</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01HS018721</GrantID>
<Acronym>HS</Acronym>
<Agency>AHRQ HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>T32 AG021885</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>K07AG033174</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R01AG027017</GrantID>
<Acronym>AG</Acronym>
<Agency>NIA NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2014</Year>
<Month>12</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Ann Pharmacother</MedlineTA>
<NlmUniqueID>9203131</NlmUniqueID>
<ISSNLinking>1060-0280</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D054795">Incretins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D045162">Thiazolidinediones</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9100L32L2N</RegistryNumber>
<NameOfSubstance UI="D008687">Metformin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2013 Jun 07;346:f3680</RefSource>
<PMID Version="1">23748128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2013 Sep 25;310(12 ):1227-8</RefSource>
<PMID Version="1">24008265</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Psychiatr Serv. 2013 Apr 1;64(4):324-30</RefSource>
<PMID Version="1">23280376</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 1999 Mar;52(3):199-207</RefSource>
<PMID Version="1">10210237</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Res Social Adm Pharm. 2013 Nov-Dec;9(6):666-87</RefSource>
<PMID Version="1">23333430</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gastroenterol. 2013 Jun;48(6):721-7</RefSource>
<PMID Version="1">23053420</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Gen Intern Med. 2006 Jul;21(7):694-7</RefSource>
<PMID Version="1">16808768</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2012 Jun;55(6):1577-96</RefSource>
<PMID Version="1">22526604</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Health Care Financ Rev. 2007 Summer;28(4):15-30</RefSource>
<PMID Version="1">17722748</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2013 Apr 18;368(16):1465-8</RefSource>
<PMID Version="1">23520983</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Feb 27;370(9):794-7</RefSource>
<PMID Version="1">24571751</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Epidemiol. 2005 Jan;58(1):98-102</RefSource>
<PMID Version="1">15649677</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2011 Jun 21;154(12):833-7, W-301</RefSource>
<PMID Version="1">21690598</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2013 Jul;36(7):2118-25</RefSource>
<PMID Version="1">23645885</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2013 Jul;36(7):2126-32</RefSource>
<PMID Version="1">23645884</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Arch Intern Med. 2000 Dec 11-25;160(22):3401-5</RefSource>
<PMID Version="1">11112232</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2011 Feb;20(2):209-13</RefSource>
<PMID Version="1">21254293</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Am Geriatr Soc. 2013 Nov;61(11):2020-6</RefSource>
<PMID Version="1">24219204</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>JAMA. 2008 Apr 23;299(16):1922-8</RefSource>
<PMID Version="1">18430911</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2013 Jul 16;159(2):105-14</RefSource>
<PMID Version="1">23752663</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Am J Med. 2003 Dec 15;115(9):715-20</RefSource>
<PMID Version="1">14693324</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Diabetes Complications. 2012 Jul-Aug;26(4):301-7</RefSource>
<PMID Version="1">22658408</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2012 Feb 9;366(6):530-8</RefSource>
<PMID Version="1">22316446</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007004" MajorTopicYN="N">Hypoglycemic Agents</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054795" MajorTopicYN="N">Incretins</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D054524" MajorTopicYN="N">Medicare Part D</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045162" MajorTopicYN="N">Thiazolidinediones</DescriptorName>
<QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS785968</OtherID>
<OtherID Source="NLM">PMC4876962</OtherID>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Medicare</Keyword>
<Keyword MajorTopicYN="N">diabetes</Keyword>
<Keyword MajorTopicYN="N">pharmacoepidemiology</Keyword>
<Keyword MajorTopicYN="N">regional variation</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2014</Year>
<Month>12</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2015</Year>
<Month>8</Month>
<Day>25</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">25515869</ArticleId>
<ArticleId IdType="pii">1060028014563951</ArticleId>
<ArticleId IdType="doi">10.1177/1060028014563951</ArticleId>
<ArticleId IdType="pmc">PMC4876962</ArticleId>
<ArticleId IdType="mid">NIHMS785968</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Pennsylvanie</li>
</region>
<settlement><li>Pittsburgh</li>
</settlement>
<orgName><li>Université de Pittsburgh</li>
</orgName>
</list>
<tree><country name="États-Unis"><region name="Pennsylvanie"><name sortKey="Marcum, Zachary A" sort="Marcum, Zachary A" uniqKey="Marcum Z" first="Zachary A" last="Marcum">Zachary A. Marcum</name>
</region>
<name sortKey="Donohue, Julie M" sort="Donohue, Julie M" uniqKey="Donohue J" first="Julie M" last="Donohue">Julie M. Donohue</name>
<name sortKey="Driessen, Julia" sort="Driessen, Julia" uniqKey="Driessen J" first="Julia" last="Driessen">Julia Driessen</name>
<name sortKey="Gellad, Walid F" sort="Gellad, Walid F" uniqKey="Gellad W" first="Walid F" last="Gellad">Walid F. Gellad</name>
<name sortKey="Thorpe, Carolyn T" sort="Thorpe, Carolyn T" uniqKey="Thorpe C" first="Carolyn T" last="Thorpe">Carolyn T. Thorpe</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000302 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000302 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:25515869
   |texte=   Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:25515869" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a PittsburghV1

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.

Regional variation in use of a new class of antidiabetic medication among medicare beneficiaries: the case of incretin mimetics.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki